AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10897186 — intervention group
Group type: COMPARATOR
Intervention: Dissemination package with implementation manuals only
Number of subjects: 74
Study 8832449 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA morphine with D = 1 mg, LI = 6 min (Group 1‐6)
Number of subjects: 75
Study 8832449 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA morphine with D = 1.5 mg, LI = 9 min (Group 1.5‐9)
Number of subjects: 75
Study 8832449 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA morphine with D = 2 mg, LI = 12 min (Group 2‐12)
Number of subjects: 75
Study 1418836 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (mean daily dose 8.8 mg)
Number of subjects: 125
Study 1418836 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (mean daily dose 83.7 mg)
Number of subjects: 125
Study 1418836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 6536490 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific training for compliance with walking
Number of subjects: 60
Study 6536490 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only attention
Number of subjects: 60
Study 30725077 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth‐Nominated Support Team Intervention (YST) plus Treatment as Usual (TAU)
Number of subjects: 448
Study 30725077 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 448
Study 30004900 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lipid emulsion (ILE) 5.25 mL/kg
Number of subjects: 10
Study 30004900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 26976418 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus AS (androgen suppression)
Number of subjects: 819
Study 26976418 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 819
Study 24505216 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational toolkit (received in June 2009)
Number of subjects: 933789
Study 24505216 — intervention group
Group type: COMPARATOR
Intervention: Control group (received no educational toolkit until May 2010)
Number of subjects: 933789
Study 23110040 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback intervention (20 mins/week for 4 weeks of observation, feedback, and personalized action planning)
Number of subjects: 60
Study 23110040 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback intervention (for implementing wards)
Number of subjects: 60
Study 23110040 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidelity to intervention
Number of subjects: 60
Study 20619748 — intervention group
Group type: EXPERIMENTAL
Intervention: No clinically relevant change in pain intensity in the first 3 months
Number of subjects: 628
Study 20619748 — intervention group
Group type: EXPERIMENTAL
Intervention: No clinically relevant change in disability status in the first 3 months
Number of subjects: 628
Study 20619748 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pain intensity score at baseline
Number of subjects: 628
Study 20619748 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher score for kinesiophobia
Number of subjects: 628
Study 20619748 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically relevant decrease in pain intensity in the first 3 months
Number of subjects: 628
Study 20619748 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically relevant decrease in disability status in the first 3 months
Number of subjects: 628
Study 17342480 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine 200 mg once daily for 7 days
Number of subjects: 12
Study 17342480 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg once daily for 7 days
Number of subjects: 12
Study 17342480 — intervention group
Group type: COMPARATOR
Intervention: Nevirapine 200 mg combined with itraconazole 200 mg once daily for 7 days
Number of subjects: 12
Study 16359503 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg day(-1)
Number of subjects: 36
Study 16359503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 11824492 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-family behavioral family therapy (BFT)
Number of subjects: 87
Study 11824492 — intervention group
Group type: COMPARATOR
Intervention: Relatives group (RG)
Number of subjects: 87
Study 9551874 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 180 mg-360 mg
Number of subjects: 30
Study 9551874 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5-10 mg
Number of subjects: 30
Study 9551874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8000153 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral IVN (75% nonprotein calories supplied as lipid, n = 9)
Number of subjects: 18
Study 8000153 — intervention group
Group type: COMPARATOR
Intervention: Central IVN (n = 9)
Number of subjects: 18
Study 8000153 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Peripheral IVN and Central IVN
Number of subjects: 18
Study 8000153 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral IVN
Number of subjects: 18
Study 8000153 — intervention group
Group type: COMPARATOR
Intervention: Central IVN
Number of subjects: 18
Study 2899590 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5g cephradine intramuscularly preoperatively and 1g cephradine orally before removal of the urethral catheter
Number of subjects: 142
Study 2899590 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 142
Study 31858883 — intervention group
Group type: EXPERIMENTAL
Intervention: Lionheart Camp for Kids
Number of subjects: 12
Study 29311763 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-ingredient pre-workout supplement (MIPS)
Number of subjects: 15
Study 29311763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 28142344 — intervention group
Group type: EXPERIMENTAL
Intervention: NTS group (three-site injection technique)
Number of subjects: 85
Study 28142344 — intervention group
Group type: COMPARATOR
Intervention: SSI group (single-site injection technique)
Number of subjects: 85
Study 26429605 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (mean 12.8 mg/kg every 12 hours for 7 patients, every 8 hours for 1 patient, every 24 hours for 1 patient)
Number of subjects: 9
Study 26429605 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 9
Study 24565128 — intervention group
Group type: EXPERIMENTAL
Intervention: Head rotation 45° laterally in prone position (Group II)
Number of subjects: 45
Study 24565128 — intervention group
Group type: COMPARATOR
Intervention: Strictly neutral prone position (Group I)
Number of subjects: 45
Study 21603891 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (10 mg) + Ethanol (0.3 g/kg)
Number of subjects: 14
Study 21603891 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (0.3 g/kg)
Number of subjects: 14
Study 21603891 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone (10 mg)
Number of subjects: 14
Study 21603891 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.6 g/kg)
Number of subjects: 14
Study 21603891 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (10 mg) + Ethanol (0.6 g/kg)
Number of subjects: 14
Study 21603891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 21603891 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug conditions (Oxycodone and Ethanol)
Number of subjects: 14
Study 18458039 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib 1500 mg once daily
Number of subjects: 138
Study 18458039 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib 500 mg twice daily
Number of subjects: 138
Study 18458039 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (both dosing schedules)
Number of subjects: 138
Study 17263263 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual vital capacity manoeuvre (VCM) before weaning off CPB
Number of subjects: 30
Study 17263263 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) of 10 cmH2O during CPB
Number of subjects: 30
Study 17263263 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end expiratory pressure (PEEP) of 7 cmH2O after weaning off CPB
Number of subjects: 30
Study 12973963 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol alone (1.5 mg/kg)
Number of subjects: 50
Study 12973963 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane alone (5% in oxygen)
Number of subjects: 50
Study 12973963 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined propofol-sevoflurane (1.5 mg/kg propofol followed by 5% sevoflurane in oxygen)
Number of subjects: 50
Study 11058207 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program based on self‐management (group E)
Number of subjects: 188
Study 11058207 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group C)
Number of subjects: 188
Study 9223888 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 3 l.min‐1 oxygen via a mask for initial 3 hours
Number of subjects: 24
Study 9223888 — intervention group
Group type: COMPARATOR
Intervention: Breathing room air
Number of subjects: 24
Study 8429447 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone (50 micrograms nebulized, 3 doses per day for 28 days)
Number of subjects: 13
Study 8429447 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo, 3 doses per day for 28 days)
Number of subjects: 13
Study 3597249 — intervention group
Group type: EXPERIMENTAL
Intervention: Various O2‐N2 mixtures (FIO2 = 20.93, 17.39, 14.40, 11.81%) during treadmill run
Number of subjects: 9
Study 30415610 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate (15 to 20 mg weekly)
Number of subjects: 4786
Study 30415610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4786
Study 27922745 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg q.12h
Number of subjects: 572
Study 27922745 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg q.8h
Number of subjects: 572
Study 25900168 — intervention group
Group type: EXPERIMENTAL
Intervention: Genital inflammation (elevated levels of at least 5 of 9 inflammatory cytokines)
Number of subjects: 58
Study 25900168 — intervention group
Group type: COMPARATOR
Intervention: Matched uninfected controls (no genital inflammation)
Number of subjects: 58
Study 24949292 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (1000 IU)
Number of subjects: 96
Study 24949292 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (0.9%)
Number of subjects: 96
Study 21450597 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 44
Study 21450597 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Moderate-Intensity Exercise (CME)
Number of subjects: 44
Study 21450597 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 44
Study 19410103 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized telecare management coupled with automated home-based symptom monitoring
Number of subjects: 405
Study 19410103 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 405
Study 17526535 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720
Number of subjects: 18
Study 17526535 — intervention group
Group type: COMPARATOR
Intervention: MMF
Number of subjects: 18
Study 17526535 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 to MMF conversion
Number of subjects: 18
Study 14738234 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled formoterol (18 microg)
Number of subjects: 12
Study 14738234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11960657 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone treatment
Number of subjects: 0
Study 11960657 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 9655012 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated targets viewed in isolation
Number of subjects: 0
Study 9655012 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated targets viewed sliding along one side of a larger stationary object
Number of subjects: 0
Study 9655012 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated targets viewed sliding between two larger stationary objects
Number of subjects: 0
Study 9655012 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated targets of varying sizes
Number of subjects: 0
Study 7650229 — intervention group
Group type: EXPERIMENTAL
Intervention: Transderm‐Nitro
Number of subjects: 18
Study 7650229 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrodisc
Number of subjects: 18
Study 7650229 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitro‐Dur II
Number of subjects: 18
Study 2667333 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentin
Number of subjects: 51
Study 2667333 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 51
Study 2667333 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study 1262715 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptomycin
Number of subjects: 42
Study 1262715 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 42
Study 6105907 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.05 mg . kg‐1
Number of subjects: 40
Study 6105907 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 6.0 mg . kg‐1
Number of subjects: 40
Study 30950685 — intervention group
Group type: EXPERIMENTAL
Intervention: Short response time deadlines (400 ms)
Number of subjects: 30
Study 30950685 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle response time deadlines (700 ms)
Number of subjects: 30
Study 30950685 — intervention group
Group type: EXPERIMENTAL
Intervention: Long response time deadlines (1,000 ms)
Number of subjects: 30
Study 30950685 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-context sentences
Number of subjects: 30
Study 30950685 — intervention group
Group type: EXPERIMENTAL
Intervention: High-context sentences
Number of subjects: 30
Study 30950685 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-alternative forced-choice response
Number of subjects: 30
Study 28045137 — intervention group
Group type: EXPERIMENTAL
Intervention: L. plantarum TIFN101
Number of subjects: 10
Study 28045137 — intervention group
Group type: EXPERIMENTAL
Intervention: L. plantarum WCFS1
Number of subjects: 10
Study 28045137 — intervention group
Group type: EXPERIMENTAL
Intervention: L. plantarum CIP104448
Number of subjects: 10
Study 28045137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 28045137 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (artificial stressor)
Number of subjects: 10
Study 26349025 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback device
Number of subjects: 36
Study 26349025 — intervention group
Group type: COMPARATOR
Intervention: No feedback device
Number of subjects: 36
Study 23953270 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine XR (400-800 mg)
Number of subjects: 798
Study 23953270 — intervention group
Group type: COMPARATOR
Intervention: risperidone (2-6 mg)
Number of subjects: 798
Study 21298628 — intervention group
Group type: EXPERIMENTAL
Intervention: Tears Again®
Number of subjects: 27
Study 21298628 — intervention group
Group type: EXPERIMENTAL
Intervention: Optive®
Number of subjects: 27
Study 21298628 — intervention group
Group type: EXPERIMENTAL
Intervention: Opticol®
Number of subjects: 27
Study 21298628 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 27
Study 19639375 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion rate of 50 microg x kg(‐1) x min(‐1)
Number of subjects: 24
Study 19639375 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion rate of 100 microg x kg(‐1) x min(‐1)
Number of subjects: 24
Study 19639375 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion rate of 150 microg x kg(‐1) x min(‐1)
Number of subjects: 24
Study 19639375 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion rate of 120 microg x kg(‐1) x min(‐1)
Number of subjects: 24
Study 19639375 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted infusion rate to achieve a mean concentration of 5 microg x mL(‐1)
Number of subjects: 24
Study 16798042 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline-rifampin-amikacin (ADR) regimen: doxycycline 100 mg twice a day, rifampin 10 mg/kg body weight/day every morning for eight weeks, plus 7.5 mg/kg amikacin intramuscularly twice a day for seven days.
Number of subjects: 220
Study 16798042 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline-rifampin (DR) regimen: doxycycline 100 mg twice a day and rifampin 10 mg/kg body weight/day every morning for eight weeks.
Number of subjects: 220
Study 16798042 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline-rifampin-amikacin (ADR) regimen
Number of subjects: 220
Study 16798042 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline-rifampin (DR) regimen
Number of subjects: 220
Study 15385902 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person intervention (3-module intervention totaling 18 sessions)
Number of subjects: 175
Study 15385902 — intervention group
Group type: COMPARATOR
Intervention: Delayed-intervention condition
Number of subjects: 175
Study 11896119 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus doxorubicin (30 mg/m2 every 3 weeks for a total of 360 mg/m2)
Number of subjects: 121
Study 11896119 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of doxorubicin (360 mg/m2 over 48 hours)
Number of subjects: 121
Study 11896119 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Bolus and Continuous infusion)
Number of subjects: 121
Study 10208077 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca‐P‐MFP‐urea test rinse
Number of subjects: 5
Study 10208077 — intervention group
Group type: COMPARATOR
Intervention: NaCl placebo rinse
Number of subjects: 5
Study 7885261 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate difficulty narrative texts
Number of subjects: 0
Study 7885261 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate difficulty expository texts
Number of subjects: 0
Study 7885261 — intervention group
Group type: EXPERIMENTAL
Intervention: Text difficulty (nonmonotonic function)
Number of subjects: 0
Study 2239812 — intervention group
Group type: EXPERIMENTAL
Intervention: Aconiti Tuber (prepared at 120 degrees C for 40 min)
Number of subjects: 0
Study 2239812 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 901996 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 11
Study 901996 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 11
Study 901996 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 11
Study 31044235 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg moxidectin
Number of subjects: 290
Study 31044235 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg moxidectin
Number of subjects: 290
Study 31044235 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 mg moxidectin
Number of subjects: 290
Study 31044235 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg moxidectin plus 400 mg albendazole
Number of subjects: 290
Study 31044235 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg moxidectin plus 400 mg albendazole
Number of subjects: 290
Study 31044235 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 mg moxidectin plus 400 mg albendazole
Number of subjects: 290
Study 31044235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 30834991 — intervention group
Group type: EXPERIMENTAL
Intervention: WaveOne Gold (WOG)
Number of subjects: 0
Study 30834991 — intervention group
Group type: EXPERIMENTAL
Intervention: XP‐endo Shaper (XPS)
Number of subjects: 0
Study 28199814 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg once daily
Number of subjects: 1307
Study 28199814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1307
Study 28199814 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab 40 mg every other week
Number of subjects: 1307
Study 26320479 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 15mg/m2
Number of subjects: 180
Study 26320479 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 20mg/m2
Number of subjects: 180
Study 26320479 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobaplatin 35mg/m2
Number of subjects: 180
Study 22609723 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentax‐Airwayscope (AWS)
Number of subjects: 36
Study 22609723 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope (McL)
Number of subjects: 36
Study 24149557 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance exercise (twice a week for 6 months)
Number of subjects: 38
Study 24149557 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dance exercise)
Number of subjects: 38
Study 19349290 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli sprouts (70 g/d; containing 420 micromol of SF precursor) for 8 weeks
Number of subjects: 48
Study 19349290 — intervention group
Group type: COMPARATOR
Intervention: Alfalfa sprouts (placebo) for 8 weeks
Number of subjects: 48
Study 16785289 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term umbilical vein catheter (7-10 days) followed by percutaneous central venous catheter
Number of subjects: 210
Study 16785289 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term umbilical vein catheter (up to 28 days)
Number of subjects: 210
Study 16785289 — intervention group
Group type: COMPARATOR
Intervention: Short-term umbilical vein catheter
Number of subjects: 210
Study 16785289 — intervention group
Group type: COMPARATOR
Intervention: Long-term umbilical vein catheter
Number of subjects: 210
Study 16785289 — intervention group
Group type: COMPARATOR
Intervention: Small-for-gestational-age infants (9 out of 45 developed thrombi)
Number of subjects: 210
Study 15204158 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin 25-50 mg/day for 1 month
Number of subjects: 42
Study 15204158 — intervention group
Group type: COMPARATOR
Intervention: Conventional topical treatment (betamethasone/salicylic acid ointment)
Number of subjects: 42